Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Nov;38(11):2247-2252.
doi: 10.1097/IAE.0000000000001869.

TESTOSTERONE SUPPLEMENTATION AND RETINAL VASCULAR DISEASE

Vaidehi S Dedania  1 , David N Zacks  1 , Wei Pan  2 , Brian L VanderBeek  3   4   5
Affiliations
Multicenter Study

TESTOSTERONE SUPPLEMENTATION AND RETINAL VASCULAR DISEASE

Vaidehi S Dedania et al. Retina. 2018 Nov.

Abstract

Purpose: To determine whether testosterone supplementation is associated with retinal artery occlusion (RAO) or retinal vein occlusion (RVO).

Methods: Retrospective matched cohort study using data from a large national U.S. insurance database. The testosterone cohort consisted of all male patients who filled a prescription for testosterone from 2000 to 2013. Five controls were matched on age (±3 years), sex, race, and similar time in plan (±3 months) for every exposed patient. Exclusion occurred for <2 years in the plan, <1 eye care visit, medications known to affect androgen levels, and systemic diseases associated with occlusions or increased testosterone. Cox proportional hazard regression assessed the hazard of a new diagnosis of RAO or RVO while controlling for age, race, diabetes mellitus, and hypertension.

Results: A total of 35,784 incident testosterone users were compared with 178,860 matched controls. Ninety-three (0.3%) RAOs and 50 (0.1%) RVOs were found in the testosterone cohort and contrasted with 316 (0.2%) RAOs and 232 (0.1%) RVOs in the control group. After multivariate analysis, testosterone supplementation significantly increased the hazard of RAO (hazard ratio: 1.43, 95% confidence interval: 1.12-1.81, P = 0.004), but not of RVO (hazard ratio: 1.03, 95% confidence interval: 0.74-1.42, P = 0.86).

Conclusion: Although the incidence of RAO and RVO is low in users of testosterone, supplementation therapy is associated with an increased hazard of RAO, but apparently not of RVO.

PubMed Disclaimer

Conflict of interest statement

Conflicts Of Interest: None

Figures

Figure 1
Figure 1
Flowchart demonstrating the patients excluded for each criteria and the final exposed cohort in the study.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cheung N, Klein R, Wang JJ, et al. Traditional and novel cardiovascular risk factors for retinal vein occlusion: the multiethnic study of atherosclerosis. Invest Ophthalmol Vis Sci. 2008;49(10):4297–4302. - PMC - PubMed
    1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc. 2000;98:133–141. - PMC - PubMed
    1. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117(6):1094–1101. - PubMed
    1. Brown GC, Magargal LE, Shields JA, Goldberg RE, Walsh PN. Retinal arterial obstruction in children and young adults. Ophthalmology. 1981;88:18–25. - PubMed
    1. Brown GC, Magargal LE. Central retinal artery obstruction and visual acuity. Ophthalmology. 1982;89:14–19. - PubMed

Publication types